Gastrointestinal Complications in 147 Consecutive Patients with Peritoneal Surface Malignancy Treated by Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy

Abstract EN

Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is increasingly used in the treatment of peritoneal carcinomatosis from gastrointestinal malignancies.

The purpose of this study is to reevaluate the incidence of gastrointestinal events and identify risk factors associated with this treatment approach.

Between January 1, 2006 and December 31, 2009, 147 patients with appendiceal and colorectal carcinomatosis were treated.

Gastrointestinal events were analyzed.

The overall incidence of grade I–IV gastrointestinal events was 17%.

There were 4 grade III gastrointestinal events that occurred in 4 patients and 11 grade IV gastrointestinal events that occurred in 8 patients.

On univariate analysis of grade I–IV events a statistically significant association was observed with the following variables: histological grade, peritoneal cancer index (PCI), small bowel resection, colorectal anastomosis, and the number of anastomoses performed per patient.

By multivariate analysis, PCI was identified as the only independent risk factor for gastrointestinal complications.

CRS combined with a uniform HIPEC regimen is associated with a 17% gastrointestinal morbidity rate (grade I–IV).

The frequency of gastrointestinal complications was associated with a large extent of disease measured by PCI (>30).